Krystal Biotech Reports Q1 2026 Earnings with Strong Revenue Growth
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy KRYS?
Source: seekingalpha
- Global Revenue Growth: Krystal Biotech reported net revenue of $116.4 million in Q1 2026, showcasing strong performance in global markets, particularly in VYJUVEK sales, which is expected to drive future growth.
- High Gross Margin: The company achieved a gross margin of 95% and delivered its 11th consecutive quarter of positive EPS, which not only boosts investor confidence but also provides a solid foundation for future capital operations.
- International Market Contribution: The European and Japanese markets contributed $28.9 million in net revenue, indicating the significant role these regions play in VYJUVEK's growth potential, with prospects for further market share expansion.
- R&D and Expense Outlook: The company anticipates non-GAAP R&D and SG&A expenses between $175 million and $195 million for 2026, and with over $1 billion in cash and investments, it indicates strong financial support for future R&D and market expansion.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy KRYS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on KRYS
Wall Street analysts forecast KRYS stock price to fall
9 Analyst Rating
8 Buy
1 Hold
0 Sell
Strong Buy
Current: 266.040
Low
198.00
Averages
229.25
High
278.00
Current: 266.040
Low
198.00
Averages
229.25
High
278.00
About KRYS
Krystal Biotech, Inc. is an integrated, commercial-stage biotechnology company. The Company is focused on the discovery, development, and commercialization of genetic medicines to treat diseases with high unmet medical needs. Its product candidates in various stages of clinical and preclinical development include KB407, KB408, KB707, KB105, KB801, KB803, KB304 and KB301. Its commercial product, VYJUVEK, is a redosable gene therapy, and a genetic medicine approved in the United States and Europe for the treatment of dystrophic epidermolysis bullosa. KB407 is being developed for the treatment of Cystic Fibrosis. KB408 is being developed for the treatment of Alpha-1 Antitrypsin Deficiency, a rare lung disease. KB707 is being developed for the treatment of solid tumors. KB105 is being developed for TGM1-Deficient Autosomal Recessive Congenital Ichthyosis. KB803 is a redosable eye drop formulation of B-VEC, designed for the treatment of ocular complications.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Krystal Biotech Reports Q1 2026 Earnings with Strong Revenue Growth
- Global Revenue Growth: Krystal Biotech reported net revenue of $116.4 million in Q1 2026, showcasing strong performance in global markets, particularly in VYJUVEK sales, which is expected to drive future growth.
- High Gross Margin: The company achieved a gross margin of 95% and delivered its 11th consecutive quarter of positive EPS, which not only boosts investor confidence but also provides a solid foundation for future capital operations.
- International Market Contribution: The European and Japanese markets contributed $28.9 million in net revenue, indicating the significant role these regions play in VYJUVEK's growth potential, with prospects for further market share expansion.
- R&D and Expense Outlook: The company anticipates non-GAAP R&D and SG&A expenses between $175 million and $195 million for 2026, and with over $1 billion in cash and investments, it indicates strong financial support for future R&D and market expansion.
See More
Krystal Biotech Q1 Earnings Exceed Expectations
- Strong Earnings Performance: Krystal Biotech reported a Q1 GAAP EPS of $1.83, beating expectations by $0.39, which reflects the company's robust profitability and enhances investor confidence in its financial health.
- Significant Revenue Growth: The company achieved Q1 revenue of $116.36 million, representing a 32.0% year-over-year increase and exceeding market expectations by $4.23 million, indicating sustained strong demand for its products and driving overall performance.
- Optimistic Financial Guidance: Krystal Biotech projects its FY 2026 non-GAAP R&D and SG&A expenses to be between $175 million and $195 million, reflecting confidence in future investments and strategic planning for continued growth.
- Global Expansion Plans: The company aims to launch VYJUVEK in Italy in H2 2026, targeting global market expansion while maintaining a gross margin outlook of 90%-95%, demonstrating its ambition and sustainable profitability in international markets.
See More
Krystal Biotech to Announce Q1 Earnings on May 4th
- Earnings Announcement: Krystal Biotech (KRYS) is set to announce its Q1 2023 earnings on May 4th before market open, with a consensus EPS estimate of $1.42, reflecting an 18.3% year-over-year increase, indicating ongoing improvements in profitability.
- Revenue Expectations: The anticipated revenue for Q1 is $112.13 million, representing a 27.2% year-over-year growth, which underscores strong market demand and sales performance, potentially boosting investor confidence.
- Historical Performance: Over the past two years, Krystal Biotech has only beaten EPS estimates 25% of the time and revenue estimates 50% of the time, indicating performance volatility that investors should monitor for future stability.
- Estimate Revisions: In the last three months, there have been no upward revisions to EPS estimates and one downward revision, while revenue estimates saw one upward and two downward revisions, suggesting a cautious market outlook on the company's future performance.
See More
Three Biotech Companies Worth Watching
- Krystal Biotech's Breakthrough: In 2023, Krystal Biotech received approval for Vyjuvek, a gene therapy for Dystrophic Epidermolysis Bullosa, achieving $389.1 million in revenue, a 34% year-over-year increase, indicating strong market potential in rare diseases.
- Madrigal Pharmaceuticals' FDA Approval: In 2024, Madrigal gained FDA approval for Rezdiffra, the first drug for metabolic dysfunction-associated steatohepatitis, with 2025 revenue reaching $958.4 million, a staggering 432% increase, showcasing robust growth in an emerging market.
- Exelixis' Oncology Innovations: Exelixis' Cabometyx remains the leading treatment for liver and kidney cancers, with no generic competition expected until 2030, while the company plans to launch several next-gen cancer therapies in the next five years, further solidifying its market position.
- Significant Market Potential: The combination of innovation and market demand in these three companies suggests that their stocks could yield substantial returns in the future, particularly in the ongoing developments within rare diseases and oncology.
See More
Three Biotech Stocks Worth Watching
- Krystal Biotech's Breakthrough: Focused on rare diseases, Krystal Biotech received approval for Vyjuvek, a gene therapy for Dystrophic Epidermolysis Bullosa, achieving $389.1 million in revenue in 2023, a 34% year-over-year increase, indicating strong market performance.
- Madrigal Pharmaceuticals' Market Potential: Madrigal's Rezdiffra, approved by the FDA in 2024 as the first treatment for metabolic dysfunction-associated steatohepatitis, generated $958.4 million in revenue in 2025, a staggering 432% increase, showcasing its potential in a large patient market.
- Exelixis' Innovative Drugs: Exelixis' Cabometyx, a leading treatment for liver and kidney cancers, is expected to face no generic competition until 2030, while its development of next-gen cancer therapies could further drive growth in the coming years.
- Competitive Advantages: These three companies demonstrate significant market potential and innovation capabilities, with Krystal Biotech and Madrigal expanding their product lines to enhance market share, while Exelixis maintains a strong position in oncology through robust financial performance and R&D efforts.
See More
Vertex Pharmaceuticals Faces Challenges in Cystic Fibrosis Market Dominance
- Market Dominance: Over the past decade, Vertex Pharmaceuticals has delivered market-beating returns primarily due to its monopoly in the cystic fibrosis drug market, which provides stable revenue but also exposes the company to threats from new entrants.
- Competitive Drug Development: Krystal Biotech's KB407 gene therapy has shown promising results in phase 1 studies, targeting all cystic fibrosis patients, while Vertex's drugs only address specific mutations, potentially leading to a loss of market share for Vertex.
- Diversification Strategy: To counter potential competition, Vertex has actively diversified its product lineup over the past three years, launching new drugs like Casgevy for sickle cell disease and Journavx for acute pain, with expectations for more approvals in the coming years.
- Strong Financial Performance: Despite facing competitive risks, Vertex is expected to continue delivering strong financial results, with its core products protected by patents until the late 2030s, making its stock still attractive for investors.
See More
Krystal Biotech Reports Q1 2026 Earnings with Strong Revenue Growth
- Global Revenue Growth: Krystal Biotech reported net revenue of $116.4 million in Q1 2026, showcasing strong performance in global markets, particularly in VYJUVEK sales, which is expected to drive future growth.
- High Gross Margin: The company achieved a gross margin of 95% and delivered its 11th consecutive quarter of positive EPS, which not only boosts investor confidence but also provides a solid foundation for future capital operations.
- International Market Contribution: The European and Japanese markets contributed $28.9 million in net revenue, indicating the significant role these regions play in VYJUVEK's growth potential, with prospects for further market share expansion.
- R&D and Expense Outlook: The company anticipates non-GAAP R&D and SG&A expenses between $175 million and $195 million for 2026, and with over $1 billion in cash and investments, it indicates strong financial support for future R&D and market expansion.
See More
Krystal Biotech Q1 Earnings Exceed Expectations
- Strong Earnings Performance: Krystal Biotech reported a Q1 GAAP EPS of $1.83, beating expectations by $0.39, which reflects the company's robust profitability and enhances investor confidence in its financial health.
- Significant Revenue Growth: The company achieved Q1 revenue of $116.36 million, representing a 32.0% year-over-year increase and exceeding market expectations by $4.23 million, indicating sustained strong demand for its products and driving overall performance.
- Optimistic Financial Guidance: Krystal Biotech projects its FY 2026 non-GAAP R&D and SG&A expenses to be between $175 million and $195 million, reflecting confidence in future investments and strategic planning for continued growth.
- Global Expansion Plans: The company aims to launch VYJUVEK in Italy in H2 2026, targeting global market expansion while maintaining a gross margin outlook of 90%-95%, demonstrating its ambition and sustainable profitability in international markets.
See More
Krystal Biotech to Announce Q1 Earnings on May 4th
- Earnings Announcement: Krystal Biotech (KRYS) is set to announce its Q1 2023 earnings on May 4th before market open, with a consensus EPS estimate of $1.42, reflecting an 18.3% year-over-year increase, indicating ongoing improvements in profitability.
- Revenue Expectations: The anticipated revenue for Q1 is $112.13 million, representing a 27.2% year-over-year growth, which underscores strong market demand and sales performance, potentially boosting investor confidence.
- Historical Performance: Over the past two years, Krystal Biotech has only beaten EPS estimates 25% of the time and revenue estimates 50% of the time, indicating performance volatility that investors should monitor for future stability.
- Estimate Revisions: In the last three months, there have been no upward revisions to EPS estimates and one downward revision, while revenue estimates saw one upward and two downward revisions, suggesting a cautious market outlook on the company's future performance.
See More
Three Biotech Companies Worth Watching
- Krystal Biotech's Breakthrough: In 2023, Krystal Biotech received approval for Vyjuvek, a gene therapy for Dystrophic Epidermolysis Bullosa, achieving $389.1 million in revenue, a 34% year-over-year increase, indicating strong market potential in rare diseases.
- Madrigal Pharmaceuticals' FDA Approval: In 2024, Madrigal gained FDA approval for Rezdiffra, the first drug for metabolic dysfunction-associated steatohepatitis, with 2025 revenue reaching $958.4 million, a staggering 432% increase, showcasing robust growth in an emerging market.
- Exelixis' Oncology Innovations: Exelixis' Cabometyx remains the leading treatment for liver and kidney cancers, with no generic competition expected until 2030, while the company plans to launch several next-gen cancer therapies in the next five years, further solidifying its market position.
- Significant Market Potential: The combination of innovation and market demand in these three companies suggests that their stocks could yield substantial returns in the future, particularly in the ongoing developments within rare diseases and oncology.
See More
Three Biotech Stocks Worth Watching
- Krystal Biotech's Breakthrough: Focused on rare diseases, Krystal Biotech received approval for Vyjuvek, a gene therapy for Dystrophic Epidermolysis Bullosa, achieving $389.1 million in revenue in 2023, a 34% year-over-year increase, indicating strong market performance.
- Madrigal Pharmaceuticals' Market Potential: Madrigal's Rezdiffra, approved by the FDA in 2024 as the first treatment for metabolic dysfunction-associated steatohepatitis, generated $958.4 million in revenue in 2025, a staggering 432% increase, showcasing its potential in a large patient market.
- Exelixis' Innovative Drugs: Exelixis' Cabometyx, a leading treatment for liver and kidney cancers, is expected to face no generic competition until 2030, while its development of next-gen cancer therapies could further drive growth in the coming years.
- Competitive Advantages: These three companies demonstrate significant market potential and innovation capabilities, with Krystal Biotech and Madrigal expanding their product lines to enhance market share, while Exelixis maintains a strong position in oncology through robust financial performance and R&D efforts.
See More
Vertex Pharmaceuticals Faces Challenges in Cystic Fibrosis Market Dominance
- Market Dominance: Over the past decade, Vertex Pharmaceuticals has delivered market-beating returns primarily due to its monopoly in the cystic fibrosis drug market, which provides stable revenue but also exposes the company to threats from new entrants.
- Competitive Drug Development: Krystal Biotech's KB407 gene therapy has shown promising results in phase 1 studies, targeting all cystic fibrosis patients, while Vertex's drugs only address specific mutations, potentially leading to a loss of market share for Vertex.
- Diversification Strategy: To counter potential competition, Vertex has actively diversified its product lineup over the past three years, launching new drugs like Casgevy for sickle cell disease and Journavx for acute pain, with expectations for more approvals in the coming years.
- Strong Financial Performance: Despite facing competitive risks, Vertex is expected to continue delivering strong financial results, with its core products protected by patents until the late 2030s, making its stock still attractive for investors.
See More
